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Background: Amyloidogenic D76N 2m variant escapes the intracellular quality control despite its instability.
Results: We show tridimensional structure and stability of D76N 2m assembled within MHCI compared with the wild type
protein.
Conclusion: Assembly of D76N 2m within the MHCI totally masks its misfolding propensity.
Significance:TheMHCI-mediated stabilization of amyloidogenic D76N 2m explains the failure of quality control in prevent-
ing its secretion.
To form extracellular aggregates, amyloidogenic proteins
bypass the intracellular quality control, which normally targets
unfolded/aggregated polypeptides. Human D76N 2-micro-
globulin (2m) variant is the prototype of unstable and amy-
loidogenic protein that forms abundant extracellular fibrillar
deposits.Herewe focus on the role of the class Imajor histocom-
patibility complex (MHCI) in the intracellular stabilization of
D76N 2m. Using biophysical and structural approaches, we
show that the MHCI containing D76N 2m (MHCI76) displays
stability, dissociation patterns, and crystal structure compara-
ble with those of the MHCI with wild type 2m. Conversely,
limited proteolysis experiments show a reduced protease sus-
ceptibility for D76N 2m within the MHCI76 as compared with
the free variant, suggesting that theMHCI has a chaperone-like
activity in preventing D76N 2m degradation within the cell.
Accordingly,D76N2m isnormally assembled in theMHCIand
circulates as free plasma species in a transgenic mouse model.
Amyloid-related diseases comprise an ever growing class of
human pathologies in which fold impairment or unfolding of a
specific protein lead to extracellular protein aggregation (1). To
protect from intracellular protein misfolding, human cells
adopt sophisticated recovery systems, either to help protein
molecules fold correctly or to remove and destroy unfolded/
incorrectly folded polypeptides with specific proteolytic path-
ways (2). Although the number of proteins causing misfolding
diseases in humans is a small subset of the whole proteome,
amyloidogenic proteins escape the quality control machinery.
In some cases proteins become amyloidogenic due to post-
translational modifications, which may occur after they have
passed the cellular quality checks. For example, the amyloid 
peptide, associatedwithAlzheimer disease, is generated by sub-
cellular proteolytic processing of the -amyloid precursor pro-
tein within the well known amyloidogenic pathway and then
secreted (3). On the other hand, amyloidogenic proteins often
fold properly and turn into pathologic aggregates slowly, over
many years (4). A typical example of the latter is wild type
2-microglobulin (WT 2m),4 which is the etiological agent of
dialysis-related amyloidosis (5).
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WT 2m is a well folded 99-residue protein, adopting a
-sandwich immunoglobulin fold, which is very stable under
physiological conditions. 2m is the light chain of the class I
major histocompatibility complex, a stable ternary complex
that also comprises the heavy chain and an 8–11-residue pep-
tide bound by the heavy chain (6). The MHCI is assembled in
the endoplasmic reticulum and thereafter transported to the
extracellular side of the cell membrane, to which MHCI is
anchored by a short transmembrane domain (7). During its
normal turnover, theMHCI continuously releases its 2m sub-
units, which are ultimately cleared only via the kidney.
Amyloid aggregation byWT2m occurs in patients with end
stage renal failure undergoing chronic hemodialysis treatment
in whom the protein circulates at persistently raised concentra-
tions (up to 30–40-fold the normal levels) and accumulates in
fibrillar aggregates in bones and joints (5). Recently, a new form
of fatal hereditary systemic amyloidosis, caused by previously
unknown D76N 2m mutation, was discovered (8). The pres-
entation of this severe disease is quite different from dialysis-
related amyloidosis; patients heterozygous for the D76N 2m
mutation suffer from a systemic disease involving all tissues,
except the central nervous system and the skeleton (8). The
D76N mutation remarkably decreases the stability of the vari-
ant protein and dramatically increases 2m aggregation pro-
pensity under physiological conditions (8).
The endoplasmic reticulum is known to host a complex
homeostatic system referred to as the unfolded protein
response (UPR), which targets unfolded/aggregated protein
molecules to degradation by the ubiquitin-proteasome path-
way (2). Consequently, a protein as unstable and prone to
aggregation as the D76N 2m variant should trigger the UPR
system and be efficiently degraded. However, the presence of
the variant in the plasma and the large amyloid deposits found
in the extracellular space of almost all the tissues are consistent
with efficient secretion of the D76N variant from the cells
expressing MHCI (8).
To gain insight into the mechanisms that allow D76N 2m
molecules to escape the UPR clearance system and to charac-
terize the effects of theD76Nmutated light chain on the assem-
bledMHCI (hereinafter namedMHCI76), a thorough structural
and biophysical study on a human MHCI76 was undertaken.
The stability of MHCI76 as compared with the WT MHCI has
been assessed by circular dichroism and mass spectrometry.
Also the crystal structure of the MHCI76, in association with a
nonapeptide, has been determined at 2.65 Å resolution and
comparedwith the crystal structure ofWTMHCI (bearingWT
2m and the same peptide), here reported at 3.1 Å resolution.
Furthermore, the dynamics of both WT and D76N 2m,
either as free species or as assembledMHCI, have been studied
by limited proteolysis. Although the experiments on mono-
meric species confirm the remarkable differences in stability
and dynamics between WT and variant 2m (9), the interac-
tions within the MHCI complex evidently control the confor-
mational variability and dynamics of the variant. Furthermore,
we used a transgenic mouse model expressing the D76N 2m
variant to demonstrate that the intracellular assembly of the
MHCI, as well as its translocation to the membrane, is not
affected by the instability or the misfolding propensity of the
D76N 2m variant.
EXPERIMENTAL PROCEDURES
Peptide Synthesis—The two nonapeptides (peptide I
YLLMWITQV; peptide II SLYAEDTAV) were prepared by
microwave-assisted solid phase synthesis (10) based on Fmoc
chemistry on preloaded 2-chlorotrityl resin (1.5 meq/g substi-
tution) using a 5-fold molar excess of 0.2 M Fmoc-protected
amino acids dissolved in dimethylformamide and using N-hy-
droxybenzotriazole/O-(benzotriazol-1-yl)-N,N,N,N-tetra-
methyluronium hexafluorophosphate/diisopropylethylamine (5:5:
10) as activators. Coupling reactions were performed for 5 min at
40 watt with amaximum temperature of 75 °C. Deprotection was
performed in two stages using 20% piperidine in dimethylform-
amide (5 and10mineach).Cleavagewasperformedusing10mlof
reagent K (TFA/phenol/water/thioanisole/ethanedithiol; 82.5/5/
5/5/2.5) for 180 min. Following cleavage, peptides were precipi-
tated out and washed using ice-cold anhydrous ethyl ether. All
peptides were purified by reverse phase HPLC using a gradient
elution of 5–70% solvent B (solvent A: water/acetonitrile/TFA
95/5/0.1; solvent B: water/acetonitrile/TFA 5/95/0.1) over 20min
ata flowrateof10ml/min.Thepurifiedpeptideswere freeze-dried
and stored at 0 °C.
MHCI Purification—The HLA-A0201 heavy chain and the
two 2m variants were expressed separately as inclusion bodies
using the BL21 (DE3) Escherichia coli strain, as described pre-
viously (11). Inclusion bodies were solubilized in 6 M guani-
diniumhydrochloride, 20mMTris-HCl, pH 8.0, and purified by
size exclusion chromatography using a Superdex 75 column.
TheMHCI component subunitswere refolded together by add-
ing 2 M 2m, 1 M HLA-A0201 heavy chain, and 10 M
peptide into the refolding buffer (100 mM Tris-HCl, 480 mM
L-arginine HCl, 2 mM EDTA, 0.5 mM oxidized glutathione, 5
mM reduced glutathione, 0.5mM4-(2-aminoethyl)-benzenesul-
fonyl fluoride hydrochloride, pH 8.0) and incubated on a mag-
netic stirrer at 4 °C for 48 h. The refolded MHCI solution was
concentrated by tangential filtration systemandpurified by size
exclusion chromatography using a Superdex 200 column and
elution buffer 150 mM NaCl, 20 mM Tris-HCl, pH 8.0. The
eluted fractions were analyzed by static light scattering and
SDS-PAGE. The presence of D76N 2mwas confirmed by chy-
motrypsin digestion and peptide sequencing by mass spec-
trometry (12).
Circular Dichroism—Thermal stability experiments were
carried out by circular dichroism (CD) on a J-810 spectropo-
larimeter (JASCOCorp., Tokyo, Japan) equipped with a Peltier
system for temperature control. All measurements on MHCI
samples were performed in 150 mM sodium chloride, 20 mM
Tris-HCl, pH8.0, at 0.2mg/ml protein concentration. The tem-
perature ramp measurements were recorded from 20 to 95 °C
(temperature slope 1.0 °C/min) in a 0.1-cm path length cuvette
and monitored at 218-nm wavelength. Monomeric D76N 2m
was studied under the same conditions previously used for
monomeric WT 2m (13).
Mass Spectrometry—Nano-ESI-MS experiments were per-
formed on a hybrid quadrupole time-of-flight mass spectrom-
eter (QSTAR Elite, AB-Sciex, Foster City, CA) equipped with a
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nano-electrospray ionization source. Samples were infused at
10 M protein concentration in 100 mM ammonium acetate,
using metal-coated borosilicate capillaries with emitter tips of
1-m internal diameter (Proxeon, Odense, Denmark). The
pH of the solution was adjusted by the addition of formic
acid to the indicated values. The following instrumental set-
ting was applied: declustering potential 50–110 V, ion spray
voltage 1000–1200 V, and curtain gas pressure 20 psi. The
sample source and the instrument interface were kept at
room temperature.
Crystallization and Structure Determination—Crystals of
MHCI76 and WT MHCI, both bearing the NY-ESO-1-derived
epitope pI (YLLMWITQV), were grown at 20 °C with sitting
drop techniques by mixing equal amounts of a 5–7 mg/ml pro-
tein solution, and the reservoir solution (1.9 M ammonium sul-
fate, 2% PEG 6000, 100 mM Tris-HCl, pH 8.0–8.2). Crystals
were cryoprotected with 20–33% glycerol and flash-frozen in
liquid nitrogen. X-ray diffraction data were collected at the
beam lines ID14-4 and BM-14 (European Synchrotron Radia-
tion Facility (ESRF), Grenoble, France) for MHCI76 and WT
MHCI, respectively. X-ray data were processed using MOSFLM
and SCALA (14, 15). The structure of MHCI76 was solved by
molecular replacement using PHASER (16); the crystal structure
of human MHCI by Webb et al. (17) (Protein Data Bank (PDB)
code 1S9W) was chosen as the search model after removal of the
MHCI bound peptide.
To determine the WT MHCI structure, whose crystals are
isomorphous with those of MHCI76, a difference Fourier anal-
ysis based on phases calculated from theMHCI76 structure was
first carried out. Using the Xtriage program (18), a pseudo-
merohedral twinning was detected for both MHCI crystals
(MHCI76 twinning fraction 18.5%,WTMHCI twinning frac-
tion 31.6%). The structures were refined using Phenix.refine
(18) and REFMAC5, applying the twin refinement protocol
(19).
TLS group refinement and Non-Crystallographic Symmetry
(NCS) restrains were introduced throughout the refinement.
Model building and analysis of the WT MHCI and MHCI76
structures were carried out using COOT (Crystallographic
Object-Oriented Toolkit) (20); figures were prepared with the
CCP4MGsoftware (21). Structure factors and coordinates have
been deposited in the Protein Data Bank under accession codes
4L3C for MHCI76 pI and 4L29 for WTMHCI pI.
Limited Proteolysis—Comparative limited proteolysis exper-
iments were performed with monomeric WT 2m and D76N
2m and on the assembled WT MHCI and MHCI76. Experi-
ments were carried out by incubating the samples with trypsin
(Sigma-Aldrich) in 50 mM ammonium bicarbonate (pH 7.5) at
37 °C, using enzyme-to-substrate ratios ranging between 1:20
and 1:500 (w/w).
The extent of the reaction was monitored on a time course
basis by sampling the incubation mixture at different time
intervals. Peptide mixtures were analyzed by MALDI-TOF
mass spectrometry using a Micromass spectrometer (Waters)
in linear mode. The sample was solubilized in 0.2% trifluoro-
acetic acid, and the protein solution was mixed 1:1 with a solu-
tion of -cyano-4-hydroxycinammic acid, 5 mg/ml in acetoni-
trile, 0.2%TFA 7:3 (v/v), applied onto themetallic sample plate,
and air-dried. Mass calibration was performed using a sample
of recombinant WT 2m as standard.
Transgenic Mice Expressing Human 2m—A wild type copy
of the human 2m gene was amplified from genomic DNA
using Phusion DNA polymerase, cloned, and sequence-veri-
fied. The D76Nmutation was then introduced by site-directed
mutagenesis (22).
Following sequence verification, transgenic mice were gen-
erated by pronuclearmicroinjection of C57BL/6J embryos with
the mutated 2m gene, including 2.1 kb and 630 bp of 5- and
3-flanking sequences, respectively. Transgenic mice were
identified by PCR using human 2m-specific primers ACT-
GAATTCACCCCCACTGA and ATGGGATGGGACTCAT-
TCAG. Five independent transgenic mice were obtained, and
lines were established from four of them.
Effect of Trypsin on D76N 2m Assembled in Natural MHCI—
Leukocytes were gently extracted from the spleen of two trans-
genic mice expressing D76N 2m and separated by Ficoll den-
sity gradient centrifugation. A suspension containing 240 
106 cells/ml was analyzed by Western blot following 15%
PAGE carried out under denaturing and reducing conditions,
and the band corresponding to monomeric human 2m was
quantified by densitometry. Based on the resulting concentra-
tion of 4 g/ml, the cell suspension was exposed to trypsin at
1:20 w/w enzyme:substrate ratio alongside a solution of mono-
meric D76N 2m in the same experimental conditions. Ali-
quots at time 0, 30, 60, 120, and 240 min were analyzed by
Western blot developed with a rabbit polyclonal anti-human
2m (2.4 g/ml, Dako) and polyclonal anti-rabbit IgG peroxi-
dase conjugate (2.5  105 g/ml, Dako) as primary and sec-
ondary antibody, respectively, and detected with chemilumi-
nescent substrate (Western Immobilon, Millipore).
RESULTS
MHCI Reconstitution—To explore potential effects on
MHCI stability by D76N variant 2m, as compared with the
WT species, the prototypic heavy chain of MHCI, HLA-A0201
(HLA-A2), was refolded in the presence of each of the two 2m
variants and of two different peptides. The selected epitopes
NY-ESO-1(Y1V9) and FR-20(Y3) are modified peptide ligand
variants from the melanoma-associated antigen NY-ESO-1
(23) and multiple myeloma-associated antigen FR-20 (24),
respectively. Both epitopes have been modified to enhance the
overall stability of HLA-A0201 complexes. Although peptide
positions 1 and 9 were mutated to Tyr and Val (phospho-Tyr1
and phospho-V9, respectively) in NY-ESO-1(Y1V9), residue 3
was changed to Tyr (phospho-Tyr3) in FR-20. The four com-
plexes thus produced were refolded using adapted well estab-
lished protocols (11), resulting in efficient production of the
HLA-A2/WT 2m/NY-ESO-1(Y1V9), HLA-A2/D76N 2m/
NY-ESO-1(Y1V9), HLA-A2/WT 2m/FR-20(Y3), and HLA-
A2/D76N 2m/FR-20(Y3) complexes, hereafter named WT
MHCI pI, MHCI76 pI, WT MHCI pII, and MHCI76 pII,
respectively.
Overall Thermodynamic Stability by Circular Dichroism—
To assess the possible effects of D76N 2m variant in the con-
text of MHCI stability, temperature ramps for WT MHCI and
MHCI76, both in complex with either pI or pII, were performed
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by monitoring protein unfolding by ellipticity in the far UV
region. The two different peptides were employed to acquire a
general trend inWTMHCI versusMHCI76 stability and to rule
out specific effects due to the chosen peptide sequence. Fig. 1A
shows the thermal unfolding of the isolated monomeric WT
2m and of the D76N variant; the resulting sigmoid curves
clearly highlight different thermal stabilities for the two vari-
ants (see also Table 1 for Tm values). The thermal unfolding
curves for WT MHCI and MHCI76, presenting the same pep-
tide, are almost perfectly superimposable; conversely, bothWT
MHCI and MHCI76 sigmoid curves are markedly shifted
according to the nature of the peptide bound to the heavy chain
(Fig. 1B). Thus, under these experimental conditions, theD76N
mutation does not affect the overall thermal stability of the
assembled MHCI complexes (Fig. 1 and Table 1).
Relative Stability by Mass Spectrometry—All the refolded
complexes were analyzed by nano-ESI-MS under nondenatur-
ating or under denaturing conditions, to analyze stoichiometry,
conformational states, relative stabilities, and dissociation pat-
terns (25–28). The spectra of WTMHCI andMHCI76 samples
are very similar (Fig. 2). Under nondenaturing conditions (Fig.
2, A and G), the predominant signals are those of the ternary
complexes, containing 2m, the heavy chain, and the peptide.
The measured mass is 45,140 Da for WT MHCI pI and
45,121Da forMHCI76 pI, slightly higher than their respective
calculatedmasses (44,927 and 44,926Da). Such a discrepancy is
typically observed for noncovalent complexes detected bymass
spectrometry, and can be explained by the trapping of solvent
molecules at protein interfaces (29). The charge-state distribu-
tion is narrow and unimodal, centered on the 14 ion in each
case (Fig. 2,A andG). Such features indicate thatWTMHCI pI
and MHCI76 pI are folded in compact, native conformations.
The ternary complex itself appears to be prone to self-associa-
tion, giving rise to peak envelopes corresponding to MHCI
dimers. Furthermore, signals of free and folded2m are present
in the m/z range of 1000–2000 (13). Because this is the only
FIGURE 1. Thermodynamic stability by circular dichroism. A and B, varia-
tion of far-UV CD signal as a function of temperature. A, thermal unfolding of
monomeric WT and D76N 2mmonitored at 202 nm. B, thermal unfolding of
WT MHCI and MHCI76 with either pI or pII monitored at 218 nm. Melting
temperatures formonomeric proteins and their assemblies as assessed using
CD curves are reported in Table 1.
TABLE 1
Melting temperatures
Tm values are assessed on far UV CD curves (Fig. 1).
Monomer MHCI pI MHCI pII
WT 2m 62.4 °Ca 67.3 °C 58.8 °C
D76N 2m 52.8 °C 65.5 °C 59.1 °C
a As in Santambrogio et al. (13).
FIGURE 2. Relative stability bymass spectrometry. A–L, nano-ESI-MS spec-
tra of WTMHCI (A–F) or MHCI76 (G–L) in 100mM ammonium acetate. A and G,
pH 7, DP 50 V, peptide I. B andH, pH 7, DP 110 V, peptide I. C and I, pH 5, DP 50
V, peptide I.D and J, pH 3.5, DP 50 V, peptide I. E and K, pH 5, DP 50 V, peptide
II. F and L, pH 3.5, DP 50 V, peptide II. Main peaks are labeled with the molec-
ular species and net charge. P, peptide; B, 2m; H, heavy chain; PBH, entire
MHCI complex.
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monomeric component detectable under the employed exper-
imental conditions, it is likely due to the presence of some free
2m in the original sample, rather than to dissociation during
electrospray. These results indicate that the D76N mutation
does not induce major changes in the MHCI structure and
assembly.
The complexes can be dissociated by increasing the declus-
tering potential (DP) at the instrument interface, resulting in
higher internal energy of the desolvated ions. The two MHCI
variants respond in a similar way. Fig. 2, B and H, show repre-
sentative spectra at intermediate DP values (110 V), at which
new signals can be recognized, indicating accumulation of free
peptide and binary 2m/heavy chain complexes. No signals are
detectable corresponding to the peptide associated with either
one of the two protein subunits, indicating that the complex
dissociation occurs preferentiallywith initial loss of the peptide,
regardless of the 2m variant. Thus, both WT MHCI and
MHCI76 appear to be characterized by a similar internal hier-
archy and similar gas phase stability. The two pI complexes also
display similar stabilities in solution as a function of pH, being
still preserved at pH 5 (Fig. 2, C and I) and completely dissoci-
ated into their individual components at pH 3.5 (Fig. 2,D and J).
Themeasured, isotope-averagedmolecularmasses are 1166Da
for peptide I, 11,860 Da forWT 2m, 11,859 Da for D76N 2m,
and 31,901 Da for the heavy chain, matching the respective
calculated values to an accuracy below75 ppm.As shown in Fig.
2,D and J, the free proteins display bimodal charge-state distri-
butions at pH 3.5, indicating the existence of large amounts of
the denatured forms.
The analysis described above was extended toWTMHCI pII
and MHCI76 pII complexes, which were analyzed under sev-
eral different solvent and instrument conditions. Again, the
response was not significantly affected by the 2m variant pres-
ent in the complex. However, major differences were detected
depending on the presence of pII, particularly in response to pH
titrations.
Spectra at pH 5 (Fig. 2, E andK) show that the pII complexes,
in contrast to the ones with pI, already dissociate into the single
components. The measured mass of WT MHCI in this case is
44,820Da (calculatedmass 44,729Da), and that ofMHCI76 is
44,817 Da (calculated mass 44,728 Da). Dissociation is com-
plete at pH 3.5 (Fig. 2, F and L), for both WT MHCI pII and
MHCI76 pII. Overall, these results indicate that the presence of
different peptides affects the relative stability of the complexes,
whereas no obvious effects of the D76N mutation on MHCI
stability or internal hierarchy of the complex could be detected
under all the conditions tested. These findings are entirely con-
sistent with the relative stabilities of the different complexes
measured by circular dichroism reported above.
Comparative Analysis of MHCI76 pI and WTMHCI pI Crys-
tal Structures—Crystal structures of MHCI76 pI and of WT
MHCI pI were determined at 2.65 and 3.1 Å resolution, respec-
tively. MHCI76 pI and WT MHCI pI produced isomorphous
crystals belonging to the orthorhombic space group P212121.
The asymmetric unit contains 14 MHCI moieties, arranged in
two juxtaposed heptameric rings (Fig. 3A), a previously unre-
ported packing for MHCI crystal structures, containing 69%
solvent content. The assembled MHCI76 14-mer, one MHCI
complex, and the mutated Asn76 residue region in the protein
are shown in Fig. 3.
In both crystal structures, the electron density is of excellent
quality for all the 14 MHCI units, except for the 87–91-residue
stretch in all 14 HLA-A2molecules. Data collection and refine-
ment statistics for MHCI76 pI and WT MHCI pI are shown in
Table 2. The 14 MHCI76 pI molecules in the asymmetric unit
show negligible structural differences, and the average root
mean square deviation was 0.29 Å/374 C atoms between
MHCI complexes.
The structure of MHCI76 pI matches very closely those of
previously reported HLA-A2 MHCI structures; e.g. the root
mean square deviation between MHCI76 and the MHCI struc-
FIGURE 3. Comparative analysis of MHCI76 pI and WT MHCI pI crystal
structures. A, ribbon representation of the MHCI76 pI assembly in the asym-
metric unit. The 14 MHCI molecules are organized in two juxtaposed hepta-
meric rings.MHCI units from the front ring aredifferently colored; those in the
back are gray. B, ribbon representation of one MHCI76 unit structure. The
D76N mutation site on 2m is detailed as a sticks model. The heavy chain,
light chain, and bound nonapeptide are in blue,magenta, and green, respec-
tively. C, stereo representation of the 2m EF loop from the MHCI76 structure
(magenta), from WT MHCI (light grey), and from the monomeric D76N 2m
(green).
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ture used as model for the molecular replacement search (PDB
code 1S9W) is 0.63 Å, calculated over all the C atoms of the
assembled complex. WT MHCI pI and the MHCI76 pI com-
plexes are alsowell superposable, displaying a rootmean square
deviation value of about 0.5 Å over the all C chains in the
asymmetric unit. The D76N mutation site is localized in the
2m E-F loop, a region far from the heavy chain contact inter-
face (Fig. 3B); accordingly, no major structural effects induced
by the D76N mutation are observed at the heavy/light chain
interface region. The 2m E-F loop within the MHCI76 struc-
ture superposes well on the corresponding region in the known
WT MHCI structures and to the E-F loop of monomeric WT
2m (Fig. 3C). A 1.5 Å shift of Tyr78 toward Asn76, observed in
the crystal structure of the monomeric D76N variant at 1.40 Å
resolution (8), is not detected in theMHCI76 structure (Fig. 3C),
perhaps as a result of the lower resolution of the MHCI76
crystals.
Overall, the crystal structure of MHCI76 pI does not appear
to be affected by the D76N mutation; globally and locally, it
matches closely the three-dimensional structures ofWTMHCI
pI. Furthermore, it is worth noting that residue 76 is not
involved in any crystal contact with symmetry-related mole-
cules within the crystal packing.
Protein Dynamics Assessment by Limited Proteolysis—Apre-
vious investigation of the conformational dynamics of the
D76N 2m variant by NMR spectroscopy suggested that under
native conditions, the main effect of the D76N mutation may
lay in an overall perturbation of the dynamic properties of the
protein (9). More precisely, an average attenuation of 5–10% of
the backbone amide NOEs should correspond to a rigidity loss
of the variant protein as compared with WT 2m that would
extensively affect its intramolecular hydrogen-bonded net-
work. To assess this hypothesis, monomeric WT and D76N
variant 2m were analyzed by limited proteolysis. This
approach has been successfully used, by us and others, to assess
the flexibility and dynamics of several proteins, including WT
2m and its N6 truncated form (30–32). Thus, limited prote-
olysis experiments were carried out on WT and D76N 2m
molecules, both in their free forms and assembledwithinMHCI
complexes. Two different series of experiments were per-
formed. Firstly, the overall susceptibility to proteolytic diges-
tion of the variant as compared with WT 2m was monitored
(Fig. 4); secondly, the specific sites sensitive to proteolytic cleav-
ages were identified (Fig. 5).
Fig. 4 clearly shows that monomeric D76N 2m is more rap-
idly degraded than theWT protein when exposed to trypsin, at
an enzyme/2m ratio of 1/200.When the same experiment was
carried out on the two 2m species associated in their MHCI
assembly, at a trypsin/MHCI ratio of 1/200, both 2m species
turned out to be fully protected from proteolytic digestion. A
high degree of protection can also be observed for WT 2m.
Significant digestion was only obtained by increasing the con-
centration of protease to a 1/20 ratio, and specific cleavages are
reported in Fig. 5.
The high cleavage specificity of trypsin allows identification
of themain sites of proteolysis and comparison of the digestion
FIGURE 4. Limitedproteolysis ofWTand variant2m. Kinetics of2m tryp-
tic degradation monitored by densitometric analysis of the corresponding
SDS-PAGE bands are shown. A 1:200 trypsin:2m ratio was used for proteo-
lytic digestion of monomeric 2m isoforms. A 1:20 trypsin:MHCI ratio was
used for the cleavage of the two 2m isoforms assembled within the MHCI.
TABLE 2
Data collection and refinement statistics for WTMHCI andMHCI76
Values in parenthesis are for the highest resolution shell.
Structure (PDB entry)
WTMHCI (4L29) MHCI76 (4L3C)
Data collection
Beam line BM-14 (ESRF) ID14–4 (ESRF)
Space group Orthorhombic P212121 Orthorhombic P212121
Unit cell constants (Å) a 101.5 b 313.3 c 314.4 a 102.1 b 314.5 c 316.2
Solvent content (%) 69.0 69.5
Resolution (Å) 53.88–3.10 (3.27–3.10) 70.63–2.65 (2.79–2.65)
Rmergea (%) 19.2 (101.5) 16.8 (90.5)
I/sig(I) 9.3 (2.2) 6.8 (1.9)
Completeness (%) 100.0 (100.0) 99.7 (99.7)
Redundancy 5.8 (5.5) 5.3 (5.4)
Unique reflections 182,537 (26405) 293,400 (42513)
Refinement
Rworkb (%) 17.06 19.91
Rfreeb (%) 20.05 21.83
Number of atoms 44,629 44,738
Ramachandran plot
Most favored region 5073 (95.61%) 5059 (95.34%)
Allowed region 233 (4.39%) 247 (4.66%)
Outliers 0 (0.00%) 0 (0.00%)
aRmerge 	hkl Ihkl 
Ihkl /	hkl Ihkl where Ihkl is the observed intensity and 
Ihkl is the average intensity.
b Rwork 	hkl Fo Fchkl/	hkl Fohkl for all data, except 5% which were used for Rfree calculation.
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pattern of the two 2m species both in their monomeric forms
and in their assembled MHCI. In particular, comparison of the
early cleavage sites can provide information on the conforma-
tional dynamics of the two proteins, whereas the late cleavages
may derive from further proteolysis of primary digestion pep-
tides and will not be discussed. Even at very low enzyme/2m
ratios (1/500) and very short incubation times (5 min), specific
cleavages are detectable for the D76N variant. In particular,
D76N 2m is rapidly cleaved at residues Arg3, Lys6, Arg12,
Lys19, Arg81, and Lys91. At the same enzyme/2m ratio, cleav-
ages become detectable in theWT protein only after 60 min of
incubation, at residues Arg3, Lys19, Lys58, and Arg81 (Fig. 5A).
The same preferential sites of cleavage are confirmed using
shorter incubation times (30 min) at higher trypsin concentra-
tion (1/200) (Fig. 5A).
Limited proteolysis therefore highlights residues Lys6, Arg12,
and Lys91 as cleavage sites specific to the D76N variant. Cleav-
age at residue Lys6 proves consistent with the NMR evidence
for the long distance destabilizing effect on the 2m A strand,
linked to the D76N mutation (9). It is worth mentioning that
trypsin cleavage at residue 6 is a primary event in the controlled
proteolysis of WT 2m fibrils, whereas the same cleavage does
not occur in native WT 2m in solution (32, 33); most impor-
tantly, destabilization of 2m A strand is pivotal for 2m amy-
loid aggregation (31). Thus, considering the cleavage at residue
Lys6 as a sign of increased structural dynamics, the proteolytic
event is consistent with the high aggregation propensity of the
D76Nvariant. The cleavage at residueArg12, located at the edge
of the A strand, confirms the increased flexibility of the A
strand linked to the D76N mutation. Conversely, the early
cleavage at Lys91, occurring rapidly in D76N variant 2m, indi-
cates a destabilization of the G strand; residue Lys91 plays a role
in structuring theG strandwith hydrogen bonds to residues 82,
83, and 89. Conservation of this H-bonded network is essential
for the stability of the G strand.
The investigation of specific cleavage sites on both 2m
variants, assembled in their respective MHCI, confirms a
remarkable protective effect of the heavy chain on the two
2m species. The digestion patterns of WT MHCI and
MHCI76, at 1/20 enzyme/protein ratios, are very similar in
terms of cleavage specificity and kinetics of digestion. Inter-
estingly, the three early proteolysis sites observed in free
FIGURE5.Locationofproteolytic sites.A, trypsin cleavage sites inD76NandWT2m for times shownandenzyme:protein ratios of 1:500 for the variant; 1/500
and 1/200 for WT 2m. B, trypsin cleavage sites in D76N variant and WT 2m within the MHCI complex.
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D76N (Lys6, Arg12, Lys91) remain uncleaved following asso-
ciation with the heavy chain. In this respect, whereas Arg12 is
indeed buried in the assembled MHCI (hence protected
from protease access), Lys6 and Lys91 are both solvent-acces-
sible residues in the assembled MHCI. Therefore, the
absence of proteolytic cleavage at these two sites might
derive from a decrease in 2m conformational fluctuations
and from an overall stabilization of the hydrogen-bonded
networks in these solvent-accessible protein regions.
Expression and Localization of the D76N Variant in Vivo—
Wehave created transgenicmice expressingD76N variant2m
to provide a mouse model of systemic 2m amyloidosis. The
characterization of this model will be reported elsewhere, but
here we show the cell surface expression of D76N variant 2m
in the MHCI complex. Although the transgenic mice do not
express human class I heavy chains, it is well established that
normal human 2m associates with mouse class I heavy chains
(34, 35). Indeed leukocytes in blood films of transgenic mice
were specifically stained following incubation with a directly
labeled monoclonal antibody specific for human 2m, whereas
those of nontransgenic mice were not (Fig. 6, A–C). This result
is consistent with cell surface localization of human D76N var-
iant 2m but, although the cells were not permeabilized, it is
conceivable that the signal reflects the 2m protein within the
cells. Cell surface localization of D76N 2m was therefore also
assessed in living cells by FACS analysis following incubationwith
FITC-labeledmonoclonal anti-human2mantibody.Cells ofnor-
mal and 2m knock-out mice gave indistinguishable patterns of
background fluorescence, whereas D76N 2m transgenic mouse
cells had significantly higher signal (Fig. 6D), showing that
human D76N 2m is present on the cell surface. Detection of
transgenicD76N2m in the serumof transgenicmice by ELISA
(not shown) andWestern blotting (Fig. 6E) at levels comparable
with or higher than those normally observed in humans pro-
vides further evidence that D76N 2m escapes cellular quality
control mechanisms, and is consistent with the in vitro obser-
vation, which shows that the assembly of 2m within the com-
plex masks its intrinsic misfolding propensity.
To confirm whether the natural form of D76N 2m is pro-
tected from the proteolytic cleavage when assembled in the
MHCI complex in its physiological environment, we have
exposed mononucleated cells, extracted from two spleens of
our transgenic mice, to trypsin, and we have monitored the
digestion of the 2m variant. The results reported in Fig. 7 indi-
cate that the protein is highly protected from digestion when
physiologically assembled in a membrane-anchored MHCI.
Our data confirm the results obtained for the soluble recombi-
nantMHCI complex and suggest that the cell membranemight
contribute to stabilize the protein and protect it from proteol-
FIGURE 6. Human 2m expression in human D76N 2m transgenic mice.
D76N 2m is expressed by three independent transgenic lines of mice (Tg2,
Tg4, and Tg11), all on the wild type C57BL/6J background. A–C, direct immu-
nofluorescence of blood films stained with FITC-labeled anti-human 2m
monoclonal antibody B2M-01. In each panel, a single representative leuko-
cyte is shown, identified by counterstaining with the blue fluorescent DNA
stainHoechst 33342; note thatmost cells visible in each field are erythrocytes,
which are intrinsically autofluorescent, lack 2m on the surface, and do not
possess nuclei. A, negative control nontransgenic C57BL/6J mouse showing
minimal signal; B and C, leukocytes of transgenic mice of lines Tg2 and Tg4
show a bright halo of D76N 2m staining. D, FACS analysis of live peripheral
blood leukocytes demonstrating cell surface expression of D76N 2m (green
line, Tg11 mouse). The FACS profiles of control nontransgenic littermate
(blue) andmouse 2m knockouts (red) are indistinguishable, confirming that
the anti-human 2mmonoclonal antibody lacks cross-reactivity with endog-
enous mouse 2m. E, Western blot analysis shows expression of free human
2m in the blood of D76N2m transgenicmice (lines Tg2, Tg4, and Tg11) as a
12-kDa band co-migrating with pure recombinant D76N 2m (100 or 10 ng
loaded, as indicated). No signal was detected in wild type C57Bl/6J (WT) or in
knock-outmice (KO) that do not express endogenous2m; 1l of serumwas
loaded in each case.
FIGURE 7.D76N2m transgenic leukocytes exposed to trypsin. Shown is aWestern blot of D76N2m (4g/ml) in bothmonomeric and transgenicmouse
leukocyte-associated forms at time 0, 30, 60, 120, and 240min after trypsin digestion at a 1:20 enzyme:substrate ratio. Controls of recombinant human variant
2m are also included (a, 1.25 g/ml; b, 2.5 g/ml; c, 5 g/ml). The leukocytes were obtained from line 4 transgenic mice.
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ysis. Indeed it has been predicted that a significant surface of
2m is in contact with the membrane and therefore not even
accessible tomonoclonal antibodies recognizing epitopes in the
2m C-terminal region (36).
DISCUSSION
Although human cells adopt sophisticated and potent systems
to control andminimize protein misfolding (2), a limited number
of proteins manage to escape the cellular quality control and
aggregate into amyloids. Proteins responsible for amyloid-related
disorderseither showtheiramyloidogenicpropensityafterpassing
the cell quality test or are stable proteins that begin to aggregate
only under specific pathophysiological conditions (i.e. an abnor-
mally elevatedplasmaconcentration) (37).TheD76Nvariant2m
appears to be an odd case in this context. On the one hand, this
2m variant is extremely prone to misfold and self-aggregate
under physiological conditions, even at very low concentrations
(8). On the other hand, in patients, the D76N variant is neither
efficiently recognized nor destroyed by the UPR system, having
been identified in massive extracellular amyloid deposits (8).
Our data explain these apparently contrasting observa-
tions. Once 2m is synthesized in the cell, it is promptly
assembled together with a heavy chain and a peptide to form
the MHCI, which is then transported to the cell surface (7).
In this way, the amyloidogenic D76N 2m variant has only a
transient existence intracellularly as an isolated chain. Our
data show that the association within the MHCI has a
remarkable stabilizing effect on the D76N 2m variant.
Despite themuchreduced stability of the isolatedD76Nvariant
as compared with WT 2m, its structure, stability, and dynamics
closelymatch thoseofWT2monceassembledwithin theMHCI.
In particular, the results of limited proteolysis indicate that the
interactionwith the heavy chain induces an overall stabilization of
the variant 2m, which extends beyond the heavy chain associa-
tion interface.Therefore, the assembly of theMHCIwould act as a
chaperone that stabilizes the variant and protects the cell from
D76N 2m aggregation. However, in fulfilling such a role, the
MHCI76moleculesmaskandhide themisfoldingpropensityof the
D76Nvariant that escapes from theUPRandother cellular quality
control pathways. Hence, although MHCI76 is crucial for the
transfer of this life-threatening2mvariantoutof the cell, it acts as
a Trojan horse for translocation of the D76N 2m variant to the
membrane.Once exposed on themembrane surface, theMHCI76
undergoes the physiological shedding of 2m, and the circulating
freeD76N2mchains canultimatelydisclose theirmisfoldingand
fibrillogenic propensity.
The elucidation of the molecular effects of MHCI assembly
on the stability and dynamics of the 2m D76N variant high-
lights the potential for the therapeutic application of2m inter-
actors, including small molecules (38) or nanobodies (39),
which can stabilize the variant and protect against the amyloid
transition. It is known that 17b-estradiol decreases MHCI pro-
duction (40), and to do this, clinically acceptable treatments
may provide an additional avenue to controlD76N2m-depen-
dent systemic amyloidosis. The availability of the transgenic
mice expressing the variant will represent a valuable tool for
testing this hypothesis.
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